TELA Bio, Inc. — Form 8-K Summary
Business context and reporting period: Filed October 8, 2026, reporting results of the company’s special stockholder meeting held that day. The record date was September 8, 2026, with 45,143,410 common shares outstanding.
Meeting results and material developments
- Stockholders approved an amendment authorizing the Board, at its discretion, to effect a reverse stock split at a ratio between 1-for-5 and 1-for-15. Votes: 30,515,571 for; 80,512 against; 1,737,011 abstentions; no broker non-votes.
- Stockholders approved adjournment of the meeting, if needed to solicit additional proxies for Proposal 1. Votes: 30,757,679 for; 123,860 against; 1,451,555 abstentions; no broker non-votes.
- TELA Bio reported that Nasdaq notified it on October 5, 2026, that it had regained compliance with the minimum bid price requirement. Accordingly, the company does not intend to effect the reverse stock split at this time.
Financial information, outlook, and risks
This filing reports no revenue, earnings, cash flow, margin, debt, liquidity, or financial guidance information. It provides no new financial outlook or detailed risk or contingency discussion.
Important facts to verify
- Whether the company later decides to implement the approved reverse split and, if so, the ratio and timing.
- Whether the company maintains compliance with Nasdaq’s minimum bid price requirement.